HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Compartmental and enzyme kinetic modeling to elucidate the biotransformation pathway of a centrally acting antitrypanosomal prodrug.

Abstract
DB868 [2,5-bis [5-(N-methoxyamidino)-2-pyridyl] furan], a prodrug of the diamidine DB829 [2,5-bis(5-amidino-2-pyridyl) furan], has demonstrated efficacy in murine models of human African trypanosomiasis. A cross-species evaluation of prodrug bioconversion to the active drug is required to predict the disposition of prodrug, metabolites, and active drug in humans. The phase I biotransformation of DB868 was elucidated using liver microsomes and sandwich-cultured hepatocytes from humans and rats. All systems produced four NADPH-dependent metabolites via O-demethylation (M1, M2) and N-dehydroxylation (M3, M4). Compartmental kinetic modeling of the DB868 metabolic pathway suggested an unusual N-demethoxylation reaction that was supported experimentally. A unienzyme Michaelis-Menten model described the kinetics of M1 formation by human liver microsomes (HLMs) (K(m), 11 μM; V(max), 340 pmol/min/mg), whereas a two-enzyme model described the kinetics of M1 formation by rat liver microsomes (RLMs) (K(m1), 0.5 μM; V(max1), 12 pmol/min/mg; K(m2), 27 μM; V(max2), 70 pmol/min/mg). Human recombinant CYP1A2, CYP3A4, and CYP4F2, rat recombinant Cyp1a2 and Cyp2d2, and rat purified Cyp4f1 catalyzed M1 formation. M2 formation by HLMs exhibited allosteric kinetics (S(50), 18 μM; V(max), 180 pmol/mg), whereas M2 formation by RLMs was negligible. Recombinant CYP1A2/Cyp1a2 catalyzed M2 formation. DB829 was detected in trace amounts in HLMs at the end of the 180-min incubation and was detected readily in sandwich-cultured hepatocytes from both species throughout the 24-h incubation. These studies demonstrated that DB868 biotransformation to DB829 is conserved between humans and rats. An improved understanding of species differences in the kinetics of DB829 formation would facilitate preclinical development of a promising antitrypanosomal prodrug.
AuthorsClaudia N Generaux, Garrett R Ainslie, Arlene S Bridges, Mohamed A Ismail, David W Boykin, Richard R Tidwell, Dhiren R Thakker, Mary F Paine
JournalDrug metabolism and disposition: the biological fate of chemicals (Drug Metab Dispos) Vol. 41 Issue 2 Pg. 518-28 (Feb 2013) ISSN: 1521-009X [Electronic] United States
PMID23223498 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Isoenzymes
  • Prodrugs
  • Recombinant Proteins
  • Trypanocidal Agents
  • Cytochrome P-450 Enzyme System
Topics
  • Animals
  • Biotransformation
  • Cells, Cultured
  • Central Nervous System (drug effects)
  • Cytochrome P-450 Enzyme System (metabolism)
  • Dealkylation
  • Female
  • Hepatocytes (enzymology)
  • Humans
  • Hydroxylation
  • Isoenzymes
  • Kinetics
  • Liver (enzymology)
  • Male
  • Methylation
  • Microsomes, Liver (enzymology)
  • Models, Biological
  • Molecular Structure
  • Oxidation-Reduction
  • Prodrugs (chemistry, metabolism, pharmacology)
  • Rats
  • Recombinant Proteins (metabolism)
  • Species Specificity
  • Trypanocidal Agents (chemistry, metabolism, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: